Article

Synergistic effects of Nrf2 inhibitor, brusatol treatment in combination with lapatinib, a selective HER2 tyrosine kinase inhibitor in HER2-positive cancers

2022-04-26

Abstract excerpt

<title>Abstract</title> <p>Overexpression of human epidermal growth factor receptor 2 (HER2), a member of the HER family of receptor tyrosine kinases (RTKs), is found in many solid tumors. The dual tyrosine kinase (EGFR/HER2) inhibitor lapatinib is currently used to clinically treat HER2-positive breast cancer. However, a majority of patients do not respond to lapatinib therapy within 6 months when using lapatini...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 521b7525-0ce5-59d7-aead-e1234c5fb560
DOI: 10.21203/rs.3.rs-1564524/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Synergistic effects of Nrf2 inhibitor, brusatol treatment in combination with lapatinib, a selective HER2 tyrosine kinase inhibitor in HER2-positive cancersDOI 10.21203/rs.3.rs-1564524/v1Read

Natural Nrf2 Inhibitors: A Review of Their Potential for Cancer TreatmentSemantic proximity Read

Nrf2, the master redox switch: the Achilles' heel of ovarian cancer?Semantic proximity Read

Targeting of a novel interplay between MET Tyrosine Kinase and NRF2 enhances sensitivity to Paclitaxel in Triple Negative Breast CancerSemantic proximity Read

Modulation of Nrf2 and NF-κB Signaling Pathways by Naturally Occurring Compounds in Relation to Cancer Prevention and Therapy. Are Combinations Better Than Single Compounds?Semantic proximity Read

The Role of ERBB2/HER2 Tyrosine Kinase Receptor in the Regulation of Cell DeathSemantic proximity Read

The Dual Roles of NRF2 in Cancer.Semantic proximity Read

Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathwaySemantic proximity Read

The Prospective role of lapatinib as an adjuvant therapy in prevalent cancers: Insights from in silico analysis targeting EGFR and HER2Semantic proximity Read

Gastric cancer combination therapy by siRNA-mediated NRF2 silencing and paclitaxelSemantic proximity Read

Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachoneSemantic proximity Read

Alpelisib Exhibits a Synergistic Effect with Pyrotinib and Reverses Acquired Pyrotinib Resistance in HER2+ Breast CancerSemantic proximity Read

Gain-of-function genetic screen of the kinome reveals BRSK2 as an inhibitor of the NRF2 transcription factorSemantic proximity Read